Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study
Year: 2023
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) requires lifelong anticoagulation. Long-term outcomes of CTEPH under current anticoagulants are unclear. OBJECTIVES: The CTEPH AC registry is a prospective, nationwide cohort study comparing the safety and effectiveness of direct oral anticoagulants (DOACs) and warfarin for CTEPH. PATIENTS/METHODS: Patients with CTEPH, both tre atment-naïve and on treatment, were eligible for the registry. Inclusion criteria were patients aged ≥20 years and those who were diagnosed with CTEPH according to standard guidelines. Exclusion criteria were not specified. The primary efficacy outcome was a composite morbidity, and mortality outcome comprised all-cause death, rescue reperfusion therapy, initiation of parenteral pulmonary vasodilators, and worsened 6-minute walk distance and WHO functional class. The safety outcome was clinically relevant bleeding, including major bleeding. RESULTS: Nine hundred twenty-seven patients on oral anticoagulants at baseline were analyzed: 481 (52%) used DOACs and 446 (48%) used warfarin. The 1-, 2-, and 3-year rates of composite morbidity and mortality outcome were comparable between the DOAC and warfarin groups (2.6%, 3.1%, and 4.2% vs 3.0%, 4.8%, and 5.9%, respectively; P = .52). The 1-, 2-, and 3-year rates of clinically relevant bleeding were significantly lower in DOACs than in the warfarin group (0.8%, 2.4%, and 2.4% vs 2.5%, 4.8%, and 6.4%, respectively; P = 0.036). Multivariable Cox proportional-hazards regression models revealed lower risk of clinically relevant bleeding in the DOAC group than the warfarin group (hazard ratio: 0.35; 95% CI: 0.13-0.91; P = .032). CONCLUSION: This registry demonstrated that under current standard of care, morbidity and mortality events were effectively prevented regardless of anticoagulants, while the clinically relevant bleeding rate was lower when using DOACs compared with warfarin.
Authors: Kazuya Hosokawa, Kohtaro Abe, Kouta Funakoshi, Yuichi Tamura, Naoki Nakashima, Koji Todaka, Yu Taniguchi, Takumi Inami, Shiro Adachi, Ichizo Tsujino, Jun Yamashita, Shun Minatsuki, Nobutaka Ikeda, Hiroto Shimokawahara, Takashi Kawakami, Takeshi Ogo, Masaru Hatano, Hitoshi Ogino, Yoshihiro Fukumoto, Nobuhiro Tanabe, Hiromi Matsubara, Keiichi Fukuda, Koichiro Tatsumi, Hiroyuki Tsutsui
Institutions: Kyushu University, Kyushu University Hospital, Mita Hospital, Kobe University Hospital, Kyorin University, Nagoya University Hospital, Hokkaido University, Tokyo Medical University, The University of Tokyo, Toho University Ohashi Medical Center, Okayama Medical Center, Toranomon Hospital, National Cerebral and Cardiovascular Center, Kurume University, Chibaken Saiseikai Narashino Hospital, Keio University, Chiba University
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,750
Funders: Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, United Therapeutics Corporation, Japan Agency for Medical Research and Development, Japan Lifeline, Kowa Company, Boehringer Ingelheim Japan, Nippon Shinyaku, Eisai, Otsuka Pharmaceutical, Teijin Pharma, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical, Novartis Pharma, Pfizer Japan, Bayer Yakuhin, Japan Society for the Promotion of Science, Daiichi Sankyo Europe, Actelion Pharmaceuticals
Awards: Study of a high-precision diagnostic imaging program for undiagnosed patients with chronic thromboembolic pulmonary hypertension, レジストリを活用した慢性血栓塞栓性肺高血圧症に対するエドキサバンの適応拡大のための第III相医師主導治験, Multi-objective optimization for decision problems in medicine, 産学官連携を加速する肺高血圧症患者レジストリ Japan PH Registryの活用研究, 慢性血栓塞栓性肺高血圧症に関する多施設共同レジストリ研究, 多施設レジストリを活用し、慢性血栓塞栓性肺高血圧症に対するエドキサバンの適応拡大を目指すコンセプト策定研究
OpenAlex ID: W4363649823
